| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
RO 46-8443 is a novel, potent, selective and non-peptidic antagonist of the endothelin ETB receptor. RO 46-8443 demonstrates a selectivity of up to 2000 times for ETB receptors in terms of both functional inhibition and binding inhibitory potency. Ro 46-8443 reduced blood pressure in normotensive rats, but it created a pressor effect in SHR and DOCA rats because it blocked the ETB-mediated release of nitric oxide, which was inhibited by L-NAME. In rats treated with chronic L-NAME to hypertension, Ro 46-8443 had a depressor effect rather than a pressor effect. Therefore, Ro 46-8443 indicates that endothelial "vasorelaxant" ETB receptors have a predominant influence in DOCA rats and SHR, whereas in normotensive rats, ETB receptors appear to have a predominant role in mediating a vasoconstrictor tone.
| Targets |
ETB ( IC50 = 34-69 nM ); ETA ( IC50 = 6800 nM )
|
|---|---|
| References |
|
| Molecular Formula |
C31H35N3O8S
|
|
|---|---|---|
| Molecular Weight |
609.69
|
|
| Exact Mass |
609.214
|
|
| Elemental Analysis |
C, 61.07; H, 5.79; N, 6.89; O, 20.99; S, 5.26
|
|
| CAS # |
175556-12-4
|
|
| Related CAS # |
|
|
| PubChem CID |
5312146
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
683.1±65.0 °C at 760 mmHg
|
|
| Flash Point |
367.0±34.3 °C
|
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
|
| Index of Refraction |
1.602
|
|
| LogP |
3.22
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
11
|
|
| Rotatable Bond Count |
13
|
|
| Heavy Atom Count |
43
|
|
| Complexity |
928
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])(N([H])C1=C(C(=NC(C2C([H])=C([H])C(=C([H])C=2[H])OC([H])([H])[H])=N1)OC([H])([H])C([H])(C([H])([H])O[H])O[H])OC1=C([H])C([H])=C([H])C([H])=C1OC([H])([H])[H])(=O)=O
|
|
| InChi Key |
DRIHNVYRUGBDHI-JOCHJYFZSA-N
|
|
| InChi Code |
InChI=1S/C31H35N3O8S/c1-31(2,3)21-12-16-24(17-13-21)43(37,38)34-29-27(42-26-9-7-6-8-25(26)40-5)30(41-19-22(36)18-35)33-28(32-29)20-10-14-23(39-4)15-11-20/h6-17,22,35-36H,18-19H2,1-5H3,(H,32,33,34)/t22-/m1/s1
|
|
| Chemical Name |
4-tert-butyl-N-[6-[(2R)-2,3-dihydroxypropoxy]-5-(2-methoxyphenoxy)-2-(4-methoxyphenyl)pyrimidin-4-yl]benzenesulfonamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (3.41 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6402 mL | 8.2009 mL | 16.4018 mL | |
| 5 mM | 0.3280 mL | 1.6402 mL | 3.2804 mL | |
| 10 mM | 0.1640 mL | 0.8201 mL | 1.6402 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA